Ovulation-Induction Medications and OHSS

Fertility treatment deliberately increases follicular activity. Oral agents alter hypothalamic or estrogen signaling so the patient releases more of her own FSH and LH; injectable gonadotropins stimulate the ovaries directly; hCG then provides an LH-like signal for final oocyte maturation and ovulation. That sequence also explains the central safety problem. Too many developing follicles can produce an excessive response, and hCG can trigger ovarian hyperstimulation syndrome (OHSS). Protein-rich fluid then leaves the vascular space and collects in the abdomen or chest. The patient may look edematous while becoming intravascularly depleted. For nursing assessment, connect four points rather than memorizing isolated adverse effects: which drug was used, how the ovaries responded on ultrasound and estradiol testing, whether hCG should be withheld, and what happens after hCG is given. Letrozole is the preferred first-line pharmacologic treatment for anovulatory PCOS when no other infertility factor is present. Clomiphene remains an ovulation-induction option with specific visual and ovarian safety rules. Gonadotropins require specialist oversight because they create the greatest risk of OHSS and multiple gestation.